GWP42003-P 20 mg/kg/day Dose ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
140	Dorabe syndrome	2
144	Lennox-Gastaut syndrome	1

140. Dorabe syndrome

Clinical trials : 104 / Drugs : 61 - (DrugBank : 14) / Drug target genes : 48 - Drug target pathways : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02091375 (ClinicalTrials.gov)	March 30, 2015	17/3/2014	Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)	A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome	Epilepsy;Dravet Syndrome	Drug: GWP42003-P 20 mg/kg/day Dose;Drug: Placebo control	GW Research Ltd	NULL	Completed	2 Years	18 Years	All	120	Phase 3	United States;France;Poland;United Kingdom
2	NCT02091206 (ClinicalTrials.gov)	October 22, 2014	17/3/2014	A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)	A Double Blind, Placebo-controlled, Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome	Epilepsy;Dravet Syndrome	Drug: GWP42003-P 5 mg/kg/day Dose;Drug: Placebo control;Drug: GWP42003-P 10 mg/kg/day Dose;Drug: GWP42003-P 20 mg/kg/day Dose	GW Research Ltd	NULL	Completed	4 Years	10 Years	All	34	Phase 2	United States;United Kingdom

Clinical trials : 101 / Drugs : 68 - (DrugBank : 12) / Drug target genes : 49 - Drug target pathways : 60

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02224690 (ClinicalTrials.gov)	April 28, 2015	21/8/2014	A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults	A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.	Epilepsy;Lennox-Gastaut Syndrome	Drug: GWP42003-P 20 mg/kg/day Dose;Drug: Placebo	GW Research Ltd	NULL	Completed	2 Years	55 Years	All	171	Phase 3	United States;Netherlands;Poland